Beijing Huaren Biotechnology

Beijing Huaren Biotechnology is a clinical-stage biotechnology company headquartered in Beijing, China, dedicated to the development of innovative Chimeric Antigen Receptor T-cell (CAR-T) therapies. The company focuses on addressing unmet medical needs in hematologic malignancies and solid tumors through its proprietary cell engineering platforms. Its lead candidate, HR-001, is a CD19-targeted CAR-T therapy that has demonstrated significant efficacy in clinical trials and is currently under New Drug Application (NDA) review in China for relapsed or refractory B-cell non-Hodgkin lymphoma. Huaren Biotechnology maintains a strategic partnership with InnoCare Pharma for the development and commercialization of its lead assets. The company's pipeline also includes next-generation bispecific CAR-T cells and therapies targeting BCMA for multiple myeloma. Through its integrated R&D and GMP manufacturing capabilities, the company aims to provide high-quality and accessible cell-based immunotherapies.